NO20050418L - Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet - Google Patents
Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitetInfo
- Publication number
- NO20050418L NO20050418L NO20050418A NO20050418A NO20050418L NO 20050418 L NO20050418 L NO 20050418L NO 20050418 A NO20050418 A NO 20050418A NO 20050418 A NO20050418 A NO 20050418A NO 20050418 L NO20050418 L NO 20050418L
- Authority
- NO
- Norway
- Prior art keywords
- tie2
- tek
- pyrimidines
- activity
- formula
- Prior art date
Links
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 title 2
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 title 2
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0218168A GB0218168D0 (en) | 2002-08-06 | 2002-08-06 | Compounds |
| GB0312356A GB0312356D0 (en) | 2003-05-30 | 2003-05-30 | Compounds |
| PCT/GB2003/003275 WO2004013141A1 (en) | 2002-08-06 | 2003-08-01 | Condensed pyridines and pyrimidines with tie2 (tek) activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050418L true NO20050418L (no) | 2005-04-28 |
Family
ID=31497259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050418A NO20050418L (no) | 2002-08-06 | 2005-01-25 | Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7427616B2 (de) |
| EP (1) | EP1537112B1 (de) |
| JP (1) | JP2005538118A (de) |
| KR (1) | KR20050067383A (de) |
| AR (1) | AR041189A1 (de) |
| AT (1) | ATE323702T1 (de) |
| AU (1) | AU2003246972A1 (de) |
| BR (1) | BR0313078A (de) |
| CA (1) | CA2494421A1 (de) |
| DE (1) | DE60304718T2 (de) |
| IL (1) | IL166521A0 (de) |
| MX (1) | MXPA05001389A (de) |
| NO (1) | NO20050418L (de) |
| TW (1) | TW200407116A (de) |
| WO (1) | WO2004013141A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230089D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| JP2007511596A (ja) | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | 癌の治療において有用なピロロピリミジン化合物 |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| GB0402518D0 (en) | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| US20050187277A1 (en) * | 2004-02-12 | 2005-08-25 | Mjalli Adnan M. | Substituted azole derivatives, compositions, and methods of use |
| CA2565037A1 (en) * | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| EP1773836B1 (de) * | 2004-05-27 | 2012-09-05 | Pfizer Products Inc. | Zur behandlung von krebs geeignete pyrrolopyrimidinderivate |
| JP2008501758A (ja) | 2004-06-09 | 2008-01-24 | グラクソ グループ リミテッド | ピロロピリジン誘導体 |
| WO2006019965A2 (en) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7465726B2 (en) * | 2004-08-02 | 2008-12-16 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2.3-B]pyridines |
| RU2007109073A (ru) | 2004-08-13 | 2008-09-20 | Дженентек, Инк. (Us) | Ингибиторы для атф-зависимого фермента на основе тиазола |
| ES2465469T3 (es) | 2005-01-14 | 2014-06-05 | Gilead Connecticut, Inc. | Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa |
| ES2408318T3 (es) * | 2005-12-23 | 2013-06-20 | Glaxosmithkline Llc | Inhibidores de azaindol de las cinasas Aurora |
| EP2038289A2 (de) | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidin- und thieno-pyridazinverbindungen und anwendungsverfahren |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| WO2009098715A2 (en) | 2008-01-11 | 2009-08-13 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| WO2010011748A2 (en) | 2008-07-22 | 2010-01-28 | Biocryst Pharmaceuticals, Inc. | Synthetic intermediates and processes |
| PE20211639A1 (es) | 2009-01-15 | 2021-08-24 | Incyte Holdings Corp | Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado |
| WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| CA2790284C (en) | 2010-02-17 | 2019-01-08 | Takeda Pharmaceutical Company Limited | Thieno-pyrimidine compounds having cdc7 inhibitory activity |
| EP2603216A4 (de) * | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Heteroaryle und verwendungen davon |
| JP5902172B2 (ja) | 2010-09-08 | 2016-04-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 広範囲のインフルエンザ抗ウイルス薬としての新規ピペラジン類似体 |
| CA2812935A1 (en) | 2010-09-28 | 2012-04-05 | Bristol-Myers Squibb Company | Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals |
| WO2014079545A1 (en) * | 2012-11-20 | 2014-05-30 | Ktb Tumorforschungsgesellschaft Mbh | Thioether derivatives as protein kinase inhibitors |
| EP2733146A1 (de) * | 2012-11-20 | 2014-05-21 | KTB Tumorforschungsgesellschaft mbH | Thioetherderivate als Proteinkinase-Inhibitoren |
| AU2014292164C1 (en) | 2013-07-15 | 2018-09-27 | Basf Se | Pesticide compounds |
| JP6371851B2 (ja) * | 2013-08-27 | 2018-08-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| CA2971606A1 (en) | 2014-12-17 | 2016-06-23 | Duquesne University Of The Holy Spirit | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as antitumor agents |
| EP3632908A1 (de) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitoren der yap / taz-tead-interaktion und ihre verwendung bei der behandlung von krebs |
| CN113272308B (zh) | 2018-11-20 | 2025-03-18 | 乔治敦大学 | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 |
| EP4553080A1 (de) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleosidderivate als antivirale mittel gegen coronaviren |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD287503A5 (de) | 1988-06-13 | 1991-02-28 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung von 4-amino-2-mercapto-thieno-/2,3-d/pyrimidinen bzw. 4-amino-2-alkylthio-thieno/2,3-d/-pyrimidinen |
| DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
| US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| JP2001514484A (ja) | 1996-08-21 | 2001-09-11 | スージェン・インコーポレーテッド | タンパク質チロシンキナーゼの結晶構造 |
| TR199902301T2 (xx) | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�. |
| WO1999024440A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| JP2002514640A (ja) | 1998-05-14 | 2002-05-21 | ジー・ディー・サール・アンド・カンパニー | ｐ３８キナーゼ阻害剤としての１，５−ジアリール置換ピラゾール類 |
| KR20010052570A (ko) | 1998-06-04 | 2001-06-25 | 스티븐 에프. 웨인스톡 | 세포 유착을 억제하는 소염성 화합물 |
| SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| HK1039325B (en) | 1998-09-18 | 2006-02-24 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidines as kinase inhibitors |
| HK1039326A1 (zh) | 1998-09-18 | 2002-04-19 | Abbott Gmbh & Co. Kg | 4氨基吡咯并嘧啶作为激酶抑制剂 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| EP1175419B1 (de) | 1999-04-02 | 2003-05-28 | Bristol-Myers Squibb Pharma Company | Arylsulfonyle als faktor xa inhibitoren |
| CA2367143A1 (en) | 1999-04-02 | 2000-10-12 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase iv inhibition activity |
| US6930101B1 (en) | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| WO2001019828A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Kinase inhibitors as therapeutic agents |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2003509412A (ja) | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| US7189745B1 (en) | 1999-11-22 | 2007-03-13 | Smithkline Beecham Corporation | Compounds |
| EP1244679B1 (de) | 1999-12-17 | 2006-11-15 | Ariad Pharmaceuticals, Inc. | Purinderivate |
| US7115589B2 (en) * | 1999-12-17 | 2006-10-03 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
| EP1162196A4 (de) | 1999-12-27 | 2003-04-16 | Japan Tobacco Inc | Verbindungen mit kondensierten ringen und ihre verwendung als medikamente |
| DE60118521T2 (de) | 2000-01-07 | 2006-10-12 | Universitaire Instelling Antwerpen | Purin derivate, ihre herstellung und verwendung |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| AU2001287268A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Method of identifying inhibitors of tie-2 |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
| EP1345966A2 (de) | 2000-09-08 | 2003-09-24 | Glaxo Group Limited | Kristallisierte zytoplasmatische tie2 rezeptor-tyrosinkinase domäne und verfahren zur feststellung und zum design ihrer modulatoren |
| US20020146472A1 (en) | 2000-11-15 | 2002-10-10 | Chen Kuang Yu | Black tea extract for prevention of disease |
| AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| US20030096813A1 (en) | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| EP1463742A4 (de) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | Neue pyrazolo- und pyrrolo-pyrimidine und ihre verwendungszwecke |
| GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| JP2005508904A (ja) | 2001-09-11 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体 |
| EP1436279B8 (de) | 2001-09-21 | 2008-10-29 | Smithkline Beecham Corporation | Chemische verbindungen |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| EP1456180B1 (de) | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| TW200306191A (en) | 2002-02-22 | 2003-11-16 | Teijin Ltd | Pyrrolopyrimidine derivatives |
| RU2301233C2 (ru) | 2002-03-07 | 2007-06-20 | Ф.Хоффманн-Ля Рош Аг | Бициклические пиридины и пиримидины в качестве ингибиторов киназы р38 |
-
2003
- 2003-08-01 DE DE60304718T patent/DE60304718T2/de not_active Expired - Fee Related
- 2003-08-01 AT AT03766443T patent/ATE323702T1/de not_active IP Right Cessation
- 2003-08-01 WO PCT/GB2003/003275 patent/WO2004013141A1/en not_active Ceased
- 2003-08-01 AU AU2003246972A patent/AU2003246972A1/en not_active Abandoned
- 2003-08-01 JP JP2004525533A patent/JP2005538118A/ja active Pending
- 2003-08-01 US US10/523,401 patent/US7427616B2/en not_active Expired - Fee Related
- 2003-08-01 MX MXPA05001389A patent/MXPA05001389A/es unknown
- 2003-08-01 KR KR1020057002193A patent/KR20050067383A/ko not_active Withdrawn
- 2003-08-01 EP EP03766443A patent/EP1537112B1/de not_active Expired - Lifetime
- 2003-08-01 BR BR0313078-9A patent/BR0313078A/pt not_active Application Discontinuation
- 2003-08-01 CA CA002494421A patent/CA2494421A1/en not_active Abandoned
- 2003-08-06 TW TW092121536A patent/TW200407116A/zh unknown
- 2003-08-06 AR ARP030102827A patent/AR041189A1/es not_active Application Discontinuation
-
2005
- 2005-01-25 NO NO20050418A patent/NO20050418L/no not_active Application Discontinuation
- 2005-01-26 IL IL16652105A patent/IL166521A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2494421A1 (en) | 2004-02-12 |
| AU2003246972A1 (en) | 2004-02-23 |
| DE60304718D1 (de) | 2006-05-24 |
| US20050256140A1 (en) | 2005-11-17 |
| TW200407116A (en) | 2004-05-16 |
| BR0313078A (pt) | 2005-07-12 |
| IL166521A0 (en) | 2006-01-15 |
| WO2004013141A1 (en) | 2004-02-12 |
| ATE323702T1 (de) | 2006-05-15 |
| JP2005538118A (ja) | 2005-12-15 |
| US7427616B2 (en) | 2008-09-23 |
| EP1537112A1 (de) | 2005-06-08 |
| EP1537112B1 (de) | 2006-04-19 |
| AR041189A1 (es) | 2005-05-04 |
| MXPA05001389A (es) | 2005-04-28 |
| KR20050067383A (ko) | 2005-07-01 |
| DE60304718T2 (de) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005005167D1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
| DE602005024239D1 (de) | Pyrimidin-verbindungen als purin-rezeptorantagonisten | |
| TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
| NO20084302L (no) | 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer | |
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
| JO2768B1 (en) | Large cyclic inhibitors of hepatitis C virus | |
| AR035111A1 (es) | Procedimiento para preparar un compuesto de pirimidinona | |
| CY1107008T1 (el) | Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii | |
| PE20030940A1 (es) | Derivados de piridina y pirimidina | |
| NO20084350L (no) | Heterocykliske amider til anvendelse som farmasoytika | |
| NO20066015L (no) | Fuserte heterosykliske forbindelser | |
| DE60226875D1 (de) | Orthosubstituierte arylamide zur bekämpfung von wirbellosen schädlingen | |
| MY144895A (en) | Macrocylic inhibitors of hepatitis c virus | |
| ATE79380T1 (de) | 2-substituierte-e-kondensierte(1,2,4>triazolo(1,5-c>pyrimidine, pharmazeutische zubereitungen und ihre verwendung. | |
| NO20061126L (no) | Aminopyroner og deres anvendelse som ATM-inhibitorer | |
| WO2003028459A8 (de) | Nicotinsäure-heterocyclyl-amide und analogue pyrimidin-derivate als schädlingsbekämpfungsmittel | |
| WO2008126901A1 (ja) | 含窒素複素環化合物およびそれを含有する医薬組成物 | |
| MXPA05011270A (es) | Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3. | |
| ES2368594T3 (es) | Derivados sustituidos de ciclohexilmetilo. | |
| ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
| ATE461192T1 (de) | Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung | |
| MA33501B1 (fr) | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| ATE482933T1 (de) | Sulfopyrrolderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |